Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial

INTRODUCTION: Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases and has already showed good safety and efficacy in some solid tumours. However, evidence on the safety and feasibility of anlotinib in patients with stage IV gastric...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Juan, Wu, Dong Xue, Meng, Lu, Ji, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279648/
https://www.ncbi.nlm.nih.gov/pubmed/32499264
http://dx.doi.org/10.1136/bmjopen-2019-034685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279648/
https://www.ncbi.nlm.nih.gov/pubmed/32499264
http://dx.doi.org/10.1136/bmjopen-2019-034685

Ejemplares similares